Search Results - "S. D. Placido"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
  2. 2

    Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up by Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., Osborne, C. K., De Placido, S., Arpino, G.

    Published in Breast cancer research and treatment (01-12-2012)
    “…Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC)…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer by CIARDIELLO, F, TROIANI, T, GRIDELLI, C, CATALANO, G, DE PLACIDO, S, BIANCO, A. R, CAPUTO, F, DE LAURENTIIS, M, TORTORA, G, PALMIERI, G, DE VITA, F, DIADEMA, M. R, ORDITURA, M, COLANTUONI, G

    Published in British journal of cancer (05-06-2006)
    “…We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma : A prospective study by FONTANINI, G, LUCCHI, M, VIGNATI, S, MUSSI, A, CIARDIELLO, F, DE LAURENTIIS, M, DE PLACIDO, S, BASOLO, F, ANGELETTI, C. A, BEVILACQUA, G

    “…Tumors acquire nutrients that are essential for continued growth and an avenue for dissemination to the rest of the body by inducing angiogenesis (i.e., the…”
    Get full text
    Journal Article
  8. 8

    The prognostic value of lymphatic and blood vessel invasion in operable breast cancer by Lauria, R, Perrone, F, Carlomagno, C, De Laurentiis, M, Morabito, A, Gallo, C, Varriale, E, Pettinato, G, Panico, L, Petrella, G

    Published in Cancer (15-11-1995)
    “…This study assessed the prognostic effect of lymphatic and blood vessel invasion (LVI and BVI) on survival in a retrospective sample of 1408 patients with…”
    Get more information
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    A predictive index of axillary nodal involvement in operable breast cancer by DE LANRENTIIS, M, GALLO, C, DE PLACIDO, S, PERRONE, F, PETTINATO, G, PETRELLA, G, CARLOMAGNO, C, PANICO, L, DELRIO, L, BIANCO, A. R

    Published in British journal of cancer (01-05-1996)
    “…We investigated the association between pathological characteristics of primary breast cancer and degree of axillary nodal involvement and obtained a…”
    Get full text
    Journal Article
  14. 14

    Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer by Carlomagno, C, Perrone, F, Lauria, R, de Laurentiis, M, Gallo, C, Morabito, A, Pettinato, G, Panico, L, Bellelli, T, Apicella, A

    Published in Oncology (01-07-1995)
    “…We analyzed retrospectively the relationships and the prognostic significance of four anatomopathological features (elastosis, fibrosis, necrosis, inflammatory…”
    Get more information
    Journal Article
  15. 15
  16. 16
  17. 17

    Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study by Perrone, F, De Placido, S, Carlomagno, C, Gravina, A, De Laurentiis, M, Del Mastro, L, Gridelli, C, Pagliarulo, C, Bianco, A R

    Published in American journal of clinical oncology (01-06-1994)
    “…Twenty-one patients with anthracycline-pretreated advanced breast cancer were treated with mitomycin C plus mitoxantrone (MM), 10 mg/m2, on day 1 of a 28-day…”
    Get more information
    Journal Article
  18. 18

    Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer by Gridelli, C, Ianniello, G P, Maiorino, A, Curcio, C, D'Aprile, M, Brancaccio, L, Palmeri, S, Gentile, M, Comella, G, Pedicini, T

    Published in American journal of clinical oncology (01-04-1994)
    “…In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA…”
    Get more information
    Journal Article
  19. 19

    Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer by GRIDELLI, C, PEPE, R, INCORONATO, P, DE PLACIDO, S, PERRONE, F, BASILICO, L, RAUSA, L, FERRANTE, G, BIANCO, A. R, PALMERI, S, IACOBELLI, S, GENTILE, M, GEBBIA, V, GARUFI, C, AIROMA, G, PALMIERI, G, RUSSO, A

    Published in Cancer chemotherapy and pharmacology (01-01-1991)
    “…A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen…”
    Get full text
    Journal Article